<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta name="GENERATOR" content="Microsoft FrontPage 5.0">
<meta name="ProgId" content="FrontPage.Editor.Document">
<meta http-equiv="Content-Type" content="text/html; charset=big5">
<link rel="File-List" href="https://hantang.com/chinese/ch_Articles/cancer98.files/filelist.xml">
<title>期刊</title>
<style>
<!--
 p.MsoNormal
	{mso-style-parent:"";
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";
	margin-left:0cm; margin-right:0cm; margin-top:0cm}
-->
</style>
<!--[if !mso]>
<style>
v\:*         { behavior: url(#default#VML) }
o\:*         { behavior: url(#default#VML) }
.shape       { behavior: url(#default#VML) }
</style>
<![endif]--><!--[if gte mso 9]>
<xml><o:shapedefaults v:ext="edit" spidmax="1027"/>
</xml><![endif]-->
</head>

<body>

<p class="MsoNormal"><b><span style="font-family: 標楷體">期刊：</span></b></p>
<p class="MsoNormal"><span style="font-family: 標楷體">臨床研究期刊</span><span lang="EN-US"> 
(The Journal of Clinical Investigation)&nbsp; Volume 117&nbsp; Number 5&nbsp; May 2007</span></p>
<p class="MsoNormal"><span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal"><b><span style="font-family: 標楷體">標題：</span></b></p>
<p class="MsoNormal"><b><span style="font-family: 標楷體">以中和抗體抑制腫瘤成長因子</span><span lang="EN-US">β
</span><span style="font-family: 標楷體">可避免因放射治療引起的腫瘤加速轉移</span></b></p>
<p class="MsoNormal" style="text-autospace: none"><b><span lang="EN-US">
(Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced 
acceleration of metastatic cancer progression)</span></b></p>
<p class="MsoNormal"><span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal"><b><span style="font-family: 標楷體">作者</span></b></p>
<p class="MsoNormal"><span lang="EN-US">Swati Biswas,<sup>1</sup> Marta Guix,<sup>2</sup> 
Cammie Rinehart,<sup>2</sup> Teresa C. Dugger,<sup>2</sup> Anna Chytil,<sup>1</sup></span></p>
<p class="MsoNormal"><span lang="EN-US">Harold L. Moses,<sup>1,3,4</sup> Michael 
L. Freeman,<sup>5</sup> and Carlos L. Arteaga<sup>1,2,4</sup></span></p>
<p class="MsoNormal"><span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal"><b><span style="font-family: 標楷體">單位</span></b></p>
<p class="MsoNormal"><span style="font-family: 標楷體">屬於美國田納西州</span>
<span style="font-family: 標楷體">那什維爾</span> <span style="font-family: 標楷體">范德堡大學</span><span lang="EN-US">(Vanderbilt 
University)</span></p>
<p class="MsoNormal"><span lang="EN-US">1.</span><span style="font-family: 標楷體">癌症生物學系、</span><span lang="EN-US">2.</span><span style="font-family: 標楷體">醫學系、</span><span lang="EN-US">3.</span><span style="font-family: 標楷體">病理學系、</span><span lang="EN-US">4. 
Vanderbilt-Ingram</span><span style="font-family: 標楷體">癌症中心乳癌研究計畫</span>
<span style="font-family: 標楷體">以及</span><span lang="EN-US"> 5.</span><span style="font-family: 標楷體">放射腫瘤學系</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span style="font-family: 標楷體">摘要</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">我們探究了因癌症治療而產生的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">究竟會不會加速腫瘤的發生。我們使用了</span><i><span lang="EN-US">MMTV/PyVmT</span></i><span lang="EN-US">
</span><span style="font-family: 標楷體">此一轉移型乳癌基因的轉殖模型，指出了游離輻射（譯註</span><span lang="EN-US">1</span><span style="font-family: 標楷體">）或</span><span lang="EN-US">doxorubicin</span><span style="font-family: 標楷體">（譯註</span><span lang="EN-US">2</span><span style="font-family: 標楷體">）都會增加循環中</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">與腫瘤細胞的量，並會增加肺部的癌症轉移。這些效應都因為我們使用了泛</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">抗體而受抵銷。我們在有</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">抗體的環境下，體外培養了這些在循環中會表現多瘤病毒中等</span><span lang="EN-US">T</span><span style="font-family: 標楷體">抗原（譯註</span><span lang="EN-US">3</span><span style="font-family: 標楷體">）的腫瘤細胞，發現它們不會生長；這表示</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">在這些細胞中是一種生存的訊號。當老鼠的腫瘤不含有第二型</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">受器時，放射線就不會增加肺部的癌症轉移；這顯示至少在部分上，肺癌轉移是跟</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">在腫瘤細胞上的直接作用有關的。這些數據含示，癌症治療所產生的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">是一種幫助癌症轉移的訊號，也提供了一個原理根據，讓我們得在癌症治療時同時使用</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">抑制劑。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal"><span style="font-family: 標楷體">譯註</span><span lang="EN-US">1</span><span style="font-family: 標楷體">：此為放射性治療。</span></p>
<p class="MsoNormal"><span style="font-family: 標楷體">譯註</span><span lang="EN-US">2</span><span style="font-family: 標楷體">：此為一癌症化學治療常用藥物，俗稱「小紅莓」。</span></p>
<p class="MsoNormal"><span style="font-family: 標楷體">譯註</span><span lang="EN-US">3</span><span style="font-family: 標楷體">：此為感染此病毒之初期的產生的三種</span><span lang="EN-US">T</span><span style="font-family: 標楷體">抗原中其中一種。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span style="font-family: 標楷體">介紹</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">腫瘤成長因子</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">，既是一個腫瘤抑制基因，也是一個腫瘤啟動子。當</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">配體</span><span lang="EN-US">(ligands)</span><span style="font-family: 標楷體">結合到與其對應的絲胺酸</span><span lang="EN-US">/</span><span style="font-family: 標楷體">酥胺酸</span><span lang="EN-US">(Ser/Thr)</span><span style="font-family: 標楷體">激&#37238;跨胞膜受器後，這些受器接著就會磷酸化、活化</span><span lang="EN-US">Smad</span><span style="font-family: 標楷體">族的訊息傳遞者。被活化之後，</span><span lang="EN-US">Smad 
2</span><span style="font-family: 標楷體">、</span><span lang="EN-US">Smad 3 </span>
<span style="font-family: 標楷體">會與</span><span lang="EN-US"> Smad 4 </span>
<span style="font-family: 標楷體">結合並遷移至細胞核內，在此處調控與細胞週期停止</span><span lang="EN-US">(cell 
cycle arrest)</span><span style="font-family: 標楷體">、細胞凋亡</span><span lang="EN-US">(apoptosis)</span><span style="font-family: 標楷體">相關的基因之轉錄。</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">之所以有腫瘤抑制基因之用，即係此項調控之功。的確，在內皮細胞與基質中的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">訊息傳遞，若是喪失或減弱，都會讓內皮細胞的細胞惡性轉化</span><span lang="EN-US">(transformation)</span><span style="font-family: 標楷體">大行其道。另一方面，已有研究顯示，若將顯性且無效的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">受器引入至移轉的癌症細胞中，從上皮細胞型態轉變成間葉細胞型態的轉分化</span><span lang="EN-US">(epithelial-to-mesenchymal 
&nbsp;transdifferentiation)</span><span style="font-family: 標楷體">、能動性</span><span lang="EN-US">(motility)</span><span style="font-family: 標楷體">、侵略性</span><span lang="EN-US">(invasiveness)</span><span style="font-family: 標楷體">、以及存活率</span><span lang="EN-US">(survival)</span><span style="font-family: 標楷體">均會受到抑制。這證明在已經完全轉化的細胞中，</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">扮演了一個腫瘤啟動子的角色（於參考文獻</span><span lang="EN-US">4</span><span style="font-family: 標楷體">中有回顧）。大部分的癌都保有</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">受器，卻喪失或部分喪失了</span><span lang="EN-US">Smad</span><span style="font-family: 標楷體">依賴性的抗細胞分裂效應</span><span lang="EN-US">(Smad-dependent 
antimitogenic effect)</span><span style="font-family: 標楷體">；同時，在某些個案中，他們還會對</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">有所反應，而獲得了幫助癌症轉移的能力。進而，不論癌症細胞過度生產</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">、過度活化</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">，或是兩者兼備，都會藉由旁泌</span><span lang="EN-US">(paracrine)</span><span style="font-family: 標楷體">的方式，改變腫瘤周圍的微小環境</span><span lang="EN-US">(microenvironment)</span><span style="font-family: 標楷體">，幫助腫瘤的發生。這些資料提供了支持根據，讓我們得以設法阻斷人類癌症中的自泌性</span><span lang="EN-US">(autocrine)</span><span style="font-family: 標楷體">或旁泌性</span><span lang="EN-US">(paracrine)</span><span style="font-family: 標楷體">之</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">訊息傳遞，以達治療之目的。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">除</span><span lang="EN-US">Smad</span><span style="font-family: 標楷體">族的蛋白質外，</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">還可以刺激數種轉化的訊息傳遞路徑。之前</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">已被證實可保護轉化細胞</span><span lang="EN-US">(transformed 
cells)</span><span style="font-family: 標楷體">不受細胞凋亡之害。此類細胞反應有一種可能的機制，就是</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">誘發了</span><span lang="EN-US">PI3K</span><span style="font-family: 標楷體">和</span><span lang="EN-US">PI3K</span><span style="font-family: 標楷體">的標的物，也就是絲胺酸</span><span lang="EN-US">/</span><span style="font-family: 標楷體">酥胺酸激&#37238;</span><span lang="EN-US"> 
Akt</span><span style="font-family: 標楷體">，此訊息傳遞程序和對於癌症藥物的抗藥性是相關連的。有些對傳統化學療法有抗藥性的腫瘤會過度表現</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">，而</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">的抑制劑經證明可逆轉此種抗藥性。還有，大部分的腫瘤都會過度表現</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">配體</span><span lang="EN-US">(ligands)</span><span style="font-family: 標楷體">。在腫瘤組織與在血清中的高量</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">配體，與腫瘤轉移的復發、患者較差的癒後，均有所相關。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">在乳癌的基因轉殖模型中，</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">之訊息傳遞可加強轉移既存的乳腺腫瘤。這是受例如</span><span lang="EN-US">Neu/ErbB2</span><span style="font-family: 標楷體">或多腺瘤病毒中央Ｔ抗原</span><span lang="EN-US">(polyomavirus 
middle T antigen,<i> </i>PyVmT)</span><span style="font-family: 標楷體">等的癌症基因之誘發所致。再者，在</span><span lang="EN-US">MMTV/LTR</span><span style="font-family: 標楷體">乳腺啟動子的控制下，表現</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">癌症基因的基因轉殖鼠，經過有條件的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">誘導，只要兩個禮拜之短，轉移肺癌的機率便高了十倍。有些癌症治療已被證實會全面性地、或留在原處誘發</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">。所以我們推測，被癌症治療所誘發的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">，會提供存活訊息給這些對化療有抗藥性的腫瘤裡的細胞，或者一部分此種腫瘤中的細胞，使它們可能在治療之後，立即加速腫瘤的擴展。在此，我們使用了乳癌轉移的</span><span lang="EN-US">MMTV/PyVmT
</span><span style="font-family: 標楷體">基因轉殖模型來展示，游離輻射</span><span lang="EN-US">(ionizing 
radiation)</span><span style="font-family: 標楷體">和小紅莓</span><span lang="EN-US">(doxorubicin)</span><span style="font-family: 標楷體">提高了循環中的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度、循環中的腫瘤細胞數、以及肺部的癌症轉移。這些效應都藉由</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">中和抗體的施加，而得以抵銷。在缺乏第二型</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">受器</span><span lang="EN-US">(TβRII)</span><span style="font-family: 標楷體">的老鼠身上，放射線則沒有增加肺部的癌症轉移。這些資料暗示，癌症治療所產生的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">是腫瘤中一個幫助癌症轉移的訊號，因此也提供了原理根據，使我們在使用這些療法時，得以同時搭配使用</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">的抑制劑。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span style="font-family: 標楷體">結果</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<b><span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">
胸腔放射線處理與化學治療提高了循環中的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">量。</span></b><span style="font-family: 標楷體">我們在八週大的未交配母鼠之胸腔與骨盆內，施加了</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">的放射線。在施加放射線之後隔</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時，進行血液採集。我們在受放射處理之老鼠的血漿裡，觀察到約為控制組</span><span lang="EN-US">2</span><span style="font-family: 標楷體">倍的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">含量</span>
<span style="font-family: 標楷體">（胸腔，</span><span lang="EN-US">P=0.03</span><span style="font-family: 標楷體">；骨盆，</span><span lang="EN-US">P=0.02</span><span style="font-family: 標楷體">；圖一</span><span lang="EN-US">A</span><span style="font-family: 標楷體">）；同時，</span><span lang="EN-US">TGF-β2</span><span style="font-family: 標楷體">的量沒有改變（資料未呈現）。在八週大的</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">基因轉殖鼠中，或是在種下</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">腫瘤細胞、穩定地轉染了</span><span lang="EN-US">luciferase
</span><span style="font-family: 標楷體">表現載體的非基因轉殖鼠中，我們都得到類似的結果（分別為</span><span lang="EN-US">P=0.015</span><span style="font-family: 標楷體">與</span><span lang="EN-US">P=0.007</span><span style="font-family: 標楷體">，相較於控制組，圖一</span><span lang="EN-US">B</span><span style="font-family: 標楷體">）。在經過放射處理後，</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">的濃度有持續七天比控制組高（資料未呈現）。為了將這些結果推廣到其他的癌症治療法，我們測試了</span><span lang="EN-US">DNA</span><span style="font-family: 標楷體">嵌入劑</span><span lang="EN-US">(DNA-intercalating 
agent)</span><span style="font-family: 標楷體">與</span><span lang="EN-US">topoisomerase 
II</span><span style="font-family: 標楷體">之抑制劑</span><span lang="EN-US"> 
doxorubicin</span><span style="font-family: 標楷體">（</span><span lang="EN-US">Adriamycin</span><span style="font-family: 標楷體">）的效果如何。從第八週開始，基因轉殖鼠被施行三次腹腔注射</span><span lang="EN-US">doxorubicin 
(5 mg/kg i.p.)</span><span style="font-family: 標楷體">，每次分別間隔</span><span lang="EN-US">21</span><span style="font-family: 標楷體">天。在第十五週收集到的血漿裡發現，相較於未處理的老鼠，</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度提高了兩倍</span><span lang="EN-US">(P 
= 0.009</span><span style="font-family: 標楷體">；圖一</span><span lang="EN-US">C)</span><span style="font-family: 標楷體">，而</span><span lang="EN-US">TGF-β2</span><span style="font-family: 標楷體">濃度則是持平不變。為了要測量在放射處理後五週所取得的肺臟組織中，被活化的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">之濃度，我們使用了一種</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">生物檢驗來檢測，這檢測是使用一種會穩定表現</span><span lang="EN-US">plasminogen 
activator inhibitor-1/luciferase reporter (PAI-1/luciferase reporter) </span>
<span style="font-family: 標楷體">
的貂肺內皮細胞來運作的。相較於未受放射處理之老鼠肺組織裂解液，經過放射線處理的老鼠肺組織裂解液，誘導提升了有</span><span lang="EN-US">2</span><span style="font-family: 標楷體">倍多的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度（</span><span lang="EN-US">P=0.0008</span><span style="font-family: 標楷體">；圖一</span><span lang="EN-US">D</span><span style="font-family: 標楷體">）。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">
胸腔的放射線處理及化學治療，會增加循環中的腫瘤細胞量與增加肺部癌症轉移。</span></b><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">增強了會表現</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">腫瘤基因之腫瘤細胞的存活率，而且之前已被證實，</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">有條件地被誘發後，會在</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">基因轉殖鼠中加速乳腺腫瘤的轉移。因此，我們推測，因治療而提升的循環中</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度，可能和這個乳癌轉移模型中的循環中腫瘤細胞增加、肺部癌症轉移增加，有所關連。帶有腫瘤的</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">老鼠在第八週大時，被施行胸腔放射處理</span><span lang="EN-US">(thoracic 
irradiation)(10 Gy)</span><span style="font-family: 標楷體">直至第十三週為止。實驗終結時進行心臟穿刺以取得血液，而血液中的細胞部分，則拿去測試其在活體外生成細胞集落之能力。從未經放射處理之老鼠所取得之血液，產生了平均</span><span lang="EN-US">1.6 
± 1.5</span><span style="font-family: 標楷體">個細胞集落；而從經過放射處理之老鼠所取得之血液，於</span><span lang="EN-US">10-12</span><span style="font-family: 標楷體">天後所測量的結果是，產生了平均</span><span lang="EN-US">28.3 
± 7.6</span><span style="font-family: 標楷體">個細胞集落（</span><span lang="EN-US">P=0.02</span><span style="font-family: 標楷體">：圖二</span><span lang="EN-US">A</span><span style="font-family: 標楷體">）。</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">抗體的免疫染色證實，這些生長的細胞集落有表現癌症基因（圖二</span><span lang="EN-US">A</span><span style="font-family: 標楷體">）。循環中的活腫瘤細胞數有所增加；而和此相符合的是，我們在經放射處理的老鼠中，觀察到較未經處理之控制組</span><span lang="EN-US">17</span><span style="font-family: 標楷體">倍的肺部表面癌症轉移（</span><span lang="EN-US">P 
= 0.009</span><span style="font-family: 標楷體">；圖二</span><span lang="EN-US">B</span><span style="font-family: 標楷體">）。在被用</span><span lang="EN-US">doxorubicin</span><span style="font-family: 標楷體">處理相較於未處理之老鼠中，也在肺部癌症轉移觀察到類似的上升情形（</span><span lang="EN-US">P 
= 0.032</span><span style="font-family: 標楷體">；圖二</span><span lang="EN-US">C</span><span style="font-family: 標楷體">）。在施加</span><span lang="EN-US">doxorubicin 
24</span><span style="font-family: 標楷體">小時之後，相較於未經處理之控制組老鼠所取得之血液，也觀察到在細胞群落數目的上升（</span><span lang="EN-US">17.2 
± 3.7</span><span style="font-family: 標楷體">與</span><span lang="EN-US">7.2 ± 2 
colonies; <i>n </i>= 5; <i>P </i>= 0.007)</span><span style="font-family: 標楷體">。從老鼠的體重及一系列的腫瘤直徑數據來看，受處理與未處理的老鼠在腫瘤負荷量上並無差異，這表示</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度之差別，不能簡單地以腫瘤負荷量會隨時間增加來解釋。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">
接下來，我們檢驗了放射線所誘發之肺部癌症轉移，是否僅限於帶有腫瘤的</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">基因轉殖鼠身上。為了測試這個可能性，我們從會表現</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">之基因轉殖的乳腺癌中，取得表現</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">的腫瘤細胞，然後將其注射至非基因轉殖的同源</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">老鼠身上。這些老鼠中的腫瘤，生長在左側鼠蹊</span><span lang="EN-US">(inguinal)</span><span style="font-family: 標楷體">（四號）的乳腺脂肪墊，我們以生物發光法，觀察並估計了其轉移擴散至肺臟的情形（圖三</span><span lang="EN-US">A</span><span style="font-family: 標楷體">）。當腫瘤長到了</span><span lang="EN-US">200mm<sup>3</sup></span><span style="font-family: 標楷體">或更大時，老鼠在胸腔施加了</span><span lang="EN-US">10 
Gy </span><span style="font-family: 標楷體">
的放射線並在其餘部分施加屏障，兩週後將老鼠犧牲。相較於控制組，接受放射處理的老鼠增加了三倍的表面肺部癌症轉移</span><span lang="EN-US">(P 
= 0.005; </span><span style="font-family: 標楷體">圖三，</span><span lang="EN-US">B</span><span style="font-family: 標楷體">和</span><span lang="EN-US">C)</span><span style="font-family: 標楷體">。再者，在放射處理後</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時與兩週之後，分別有相較於控制組多</span><span lang="EN-US">8</span><span style="font-family: 標楷體">倍與</span><span lang="EN-US">5</span><span style="font-family: 標楷體">倍的循環中腫瘤細胞量（表一）。在實驗組與控制組間，原發腫瘤的生長率並無不同（資料未呈現）。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">將培養中的</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">細胞暴露在</span><span lang="EN-US">1.25 
- 7.50 Gy</span><span style="font-family: 標楷體">下，會增加其產生</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">的量（圖四</span><span lang="EN-US">A</span><span style="font-family: 標楷體">）。在以上所述之研究過程中，有既成之腫瘤的老鼠才會施加放射線處理；循環中</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度的增加，有可能是因為放射線在癌症細胞上的作用，因此我們想排除掉這個可能。我們對未交配的</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">母鼠施加了</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">的胸腔放射。在放射處理後一個小時，我們從尾部靜脈注入了表現</span>
<span lang="EN-US">PyVmT </span><span style="font-family: 標楷體">且受</span>
<span lang="EN-US">luciferase </span><span style="font-family: 標楷體">穩定轉染</span><span lang="EN-US">(stably 
transfected)</span><span style="font-family: 標楷體">的腫瘤細胞。肺臟中的腫瘤細胞負荷量</span><span lang="EN-US">(tumor 
cell burden)</span><span style="font-family: 標楷體">，是在腫瘤細胞的注入之後，使用活體內</span><span lang="EN-US">(in 
vivo)</span><span style="font-family: 標楷體">與活體外</span><span lang="EN-US">(ex 
vivo)</span><span style="font-family: 標楷體">的生物發光來監測的。經放射線處理的老鼠肺臟，表現了較控制組為高的生物發光訊號（圖四</span><span lang="EN-US">B</span><span style="font-family: 標楷體">），此訊號與人工計數之表面肺癌轉移數量是相關連的，亦與肺臟重量相關（圖四，</span><span lang="EN-US">C</span><span style="font-family: 標楷體">與</span><span lang="EN-US">D</span><span style="font-family: 標楷體">）。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TGF-β</span><span style="font-family: 標楷體">中和抗體阻斷了受放射線誘導增加之肺部癌症轉移</span></b><span style="font-family: 標楷體">。我們使用了</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">中和泛</span><span lang="EN-US">TGF-β 
IgG2</span><span style="font-family: 標楷體">抗體</span><span lang="EN-US"> (2G7 
neutralizing pan-TGF-β IgG2)</span><span style="font-family: 標楷體">來驗證，放射線所誘導增加的循環中</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度，是否在肺癌轉移中扮演一個成因的角色。這個單株抗體阻斷了所有三種哺乳類所具有的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">異構物，並且在活體中有活性。八週大的</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">基因轉殖鼠，在胸腔放射處理的</span><span lang="EN-US">2</span><span style="font-family: 標楷體">小時之前，以</span><span lang="EN-US">15mg/kg
</span><span style="font-family: 標楷體">之</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">或</span><span lang="EN-US">PBS</span><span style="font-family: 標楷體">注射至腹腔中。這些處理持續每週兩次，到第十三週為止，此時將老鼠犧牲並測量是否肺部有癌症轉移。然而有趣的是，施打</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">到未經放射線處理的老鼠中，少許增加了肺癌轉移，但在統計上並不顯著（圖五</span><span lang="EN-US">A</span><span style="font-family: 標楷體">和</span><span lang="EN-US">B</span><span style="font-family: 標楷體">）。在兩種實驗組別之間，並未存在原發腫瘤細胞負荷量的差異（資料未呈現）。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">
我們收集了血液並體外培養其細胞懸浮液，以估計在循環中的腫瘤細胞量。從未經放射處理與經過放射處理的老鼠身上，血液中取得而培養的細胞群落數，均因施加</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">而顯著地減少（圖五</span><span lang="EN-US">C</span><span style="font-family: 標楷體">）。最後，我們檢驗了在體外添加</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">以抑制</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">，是否會阻止老鼠血液中取得之腫瘤細胞群落生長。將帶有腫瘤、經過放射處理的老鼠所取得之血液，接種於含有</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">與不含有</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">的環境下，而在十天之後評估其集落生長情形。將細胞培養在存有</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">的環境下，發現會降低</span><span lang="EN-US">70%</span><span style="font-family: 標楷體">的細胞群落數（圖五</span><span lang="EN-US">D</span><span style="font-family: 標楷體">），這表示自泌性的</span><span lang="EN-US">(autocrine) 
TGF-β</span><span style="font-family: 標楷體">對於表現</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">的循環中癌症細胞，是一種存活因子。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">
放射線誘導增加肺部癌症轉移，需要腫瘤細胞內的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">受器</span></b><span style="font-family: 標楷體">。以上描述的結果顯示，因放射線誘導之循環中</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度提升，是對於循環中腫瘤細胞的存活信號，讓細胞可以移居至肺臟、在肺臟裡生長。因此我們推論，藉由移除細胞對循環中</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">的反應，以使得</span><span lang="EN-US">TβRII
</span><span style="font-family: 標楷體">不存在於</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">腫瘤中，就可以抵銷放射處理在癌症轉移上的效應。為檢驗此推論之可能，我們使用了表現</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">的腫瘤細胞，並且用</span><span lang="EN-US">Cre-Lox</span><span style="font-family: 標楷體">技術將</span><span lang="EN-US">TβRII</span><span style="font-family: 標楷體">有條件地於細胞中移除。含有或未含</span><span lang="EN-US">TGFBR2</span><span style="font-family: 標楷體">的</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">表現型腫瘤細胞株（在此之後將稱為</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox</sup> 
or PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">）是分別從</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox</sup>
</span><span style="font-family: 標楷體">及</span><span lang="EN-US"> PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">老鼠身上的乳腺癌所產生。</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox
</sup></span><span style="font-family: 標楷體">及</span><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">細胞株均以</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">之載體穩定轉染，且經由尾部靜脈注射入八週大、未交配的</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">母鼠，這些母鼠有些沒有經過放射線處理，有些則是在注射腫瘤細胞之前</span><span lang="EN-US">1</span><span style="font-family: 標楷體">小時，施加了</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">的胸腔放射。兩週後估計肺部癌症轉移情形。在被注射</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox</sup>
</span><span style="font-family: 標楷體">
細胞的老鼠裡，經放射處理之老鼠相較於控制組老鼠，發現生物發光訊號有所增加、肺部癌症轉移增加</span><span lang="EN-US">6</span><span style="font-family: 標楷體">倍；但如果老鼠之前是被注射不含有</span><span lang="EN-US">TβRII</span><span style="font-family: 標楷體">的細胞，在施加與未施加放射處理的兩組中，便沒有差別（圖六，</span><span lang="EN-US">A-C</span><span style="font-family: 標楷體">）。</span><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup>
</span><span style="font-family: 標楷體">的腫瘤結節比</span><span lang="EN-US"> PyVmT/TGFBR2<sup>flox/flox</sup>
</span><span style="font-family: 標楷體">的腫瘤結節還大，此結果與之前的一項報告是相符合的，也就是說，</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">表現型乳癌細胞之</span><span lang="EN-US">TβRII</span><span style="font-family: 標楷體">喪失，會增進肺部癌症轉移的生長。經</span><span lang="EN-US">PCR</span><span style="font-family: 標楷體">擴增腫瘤組織中取得之</span><span lang="EN-US">DNA</span><span style="font-family: 標楷體">證實了在</span><span lang="EN-US"> 
PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">細胞中，是存在基因重組的（圖六</span><span lang="EN-US">D</span><span style="font-family: 標楷體">）。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">討論</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">
我們在基因轉殖老鼠的乳癌轉移模型中，研究了癌症治療所誘發的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">是否會加速腫瘤的發生。在</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">基因轉殖鼠中，在肺部施加游離輻射或是以</span><span lang="EN-US">doxorubicin</span><span style="font-family: 標楷體">處理，都增加了循環中的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">量、循環中腫瘤細胞數以及肺部癌症轉移。循環中</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度增加、之後的癌症轉移增加，並不需要老鼠在施加處理時就擁有腫瘤，就如同我們也在放射處理後才施打腫瘤細胞的老鼠中所觀察到的。</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">會增加，並不僅限於受到胸腔放射處理的誘導，因為我們在骨盆的放射處理、以及全面性施加</span><span lang="EN-US">doxorubicin</span><span style="font-family: 標楷體">下，也都觀察到了</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">的受誘導增加。在放射處理後，循環中腫瘤細胞的增加以及腫瘤轉移的增加，都因到</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">的施加而抵銷。重要的是，循環中</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">表現型腫瘤細胞無法在有</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">的環境下進行體外培養，這也就表示了自泌性</span><span lang="EN-US">(autocrine)TGF-β</span><span style="font-family: 標楷體">對這些細胞是一種存活的訊號。這些結果與之前兩項研究是相吻合的；在這些研究中，以可溶性</span><span lang="EN-US">TβRII:Fc</span><span style="font-family: 標楷體">融合蛋白、或用反義</span><span lang="EN-US">TGF-β1(antisense 
TGF-β1)</span><span style="font-family: 標楷體">穩定性轉染加以阻斷</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">，都抑制了腫瘤細胞的能動性、存活率、滲入</span><span lang="EN-US">(intravasation)</span><span style="font-family: 標楷體">以及肺部癌症轉移。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">老鼠身上的腫瘤不含</span><span lang="EN-US">TβRII</span><span style="font-family: 標楷體">，放射線便無法在這些老鼠身上加強肺部癌症轉移。為了展示此點，我們從</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox</sup>
</span><span style="font-family: 標楷體">與</span><span lang="EN-US"> PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">之老鼠身上既成之乳腺腫瘤，取得細胞株來使用。</span><span lang="EN-US">Forrester</span><span style="font-family: 標楷體">等人曾經提出報告，以</span><span lang="EN-US">MMTV/Cre</span><span style="font-family: 標楷體">表現有條件地使</span><span lang="EN-US">TGFBR2</span><span style="font-family: 標楷體">缺失時，這些</span><span lang="EN-US">knockout 
PyVmT</span><span style="font-family: 標楷體">表現型的腫瘤發生潛伏期就變短了許多，並且表現出明顯增加的肺部癌症轉移，這是相較於</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox</sup></span><span style="font-family: 標楷體">型的腫瘤。因為我們使用了靜脈注射法，並且，我們所注入細胞株是從既成之含有</span><span lang="EN-US">TβRII</span><span style="font-family: 標楷體">與未含</span><span lang="EN-US">TβRII</span><span style="font-family: 標楷體">的腫瘤而來，所以我們的結果無法解釋</span><span lang="EN-US">Forrester</span><span style="font-family: 標楷體">等人所報導之癌症潛伏與轉移的表現。儘管我們在經放射處理的老鼠中無法排除</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">之增加，是否會影響宿主的微環境</span><span lang="EN-US">(microenvironment)</span><span style="font-family: 標楷體">與</span><span lang="EN-US">/</span><span style="font-family: 標楷體">或免疫系統，並進而幫助了腫瘤轉移之進行，我們不含有</span><span lang="EN-US">TβRII</span><span style="font-family: 標楷體">之腫瘤的結果卻強烈地顯示，癌症轉移之增加至少在部分上，是肇因於</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">在癌症細胞的直接作用。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">在腫瘤細胞中，這些潛在受循環中</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度調控的訊號反應，目前仍屬未明。然而，</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">的助癌轉移效應並不僅限於此基因轉殖模型。舉例說明，在</span><span lang="EN-US">MMTV/LTR</span><span style="font-family: 標楷體">啟動子控制下表現有活性的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">與</span><span lang="EN-US">Neu</span><span style="font-family: 標楷體">的雙基因型</span><span lang="EN-US">(bigenic)</span><span style="font-family: 標楷體">的老鼠，也表現出比</span><span lang="EN-US">MMTV/Neu</span><span style="font-family: 標楷體">更多的循環中腫瘤細胞與肺部癌症轉移。會表現</span><span lang="EN-US">Neu</span><span style="font-family: 標楷體">和具活性的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">之乳腺腫瘤細胞，能侵入</span><span lang="EN-US">Matrigel</span><span style="font-family: 標楷體">並且能在</span><span lang="EN-US">transwells</span><span style="font-family: 標楷體">上移動，但卻受可溶性的</span><span lang="EN-US">TβRII:Fc</span><span style="font-family: 標楷體">給阻斷，表示單單</span><span lang="EN-US">Neu</span><span style="font-family: 標楷體">不足以誘導出一種侵略性的表現型。再者，在會表現具活性</span><span lang="EN-US">Neu</span><span style="font-family: 標楷體">的基因轉殖腫瘤裡，若共同表現具活性的突變種</span><span lang="EN-US">Alk5</span><span style="font-family: 標楷體">和</span><span lang="EN-US">TβRI</span><span style="font-family: 標楷體">，會增加肺部血管外的癌症移轉</span><span lang="EN-US">(extravascular 
lung metastasis)</span><span style="font-family: 標楷體">，這與</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">之效應相符：也就是腫瘤周圍蛋白&#37238;、癌症細胞的附著和侵略。</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">是一個強而有力的癌症基因，我們也已經知道它會活化</span><span lang="EN-US">ErK</span><span style="font-family: 標楷體">和</span><span lang="EN-US">PI3K</span><span style="font-family: 標楷體">；但</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">竟然能對如此的腫瘤細胞具備有效的抗腫瘤移轉效果，有點不符合直覺。但是，這表示</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">可以放大癌症基因的訊號，而只要這訊號大於某一閾值，可以完全地使腫瘤移轉被觀察到；並且，相反地，在腫瘤基因已惡性轉化的細胞</span><span lang="EN-US">(oncogene-transformed 
cells)</span><span style="font-family: 標楷體">內阻斷</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">訊號時，會把這些訊號降低至比閾值更低的程度，使其無法到達癌症基因誘導癌症進行。確實如此，在鱗狀細胞癌</span><span lang="EN-US">(squamous 
cancers)</span><span style="font-family: 標楷體">中被逼著表現的顯性</span><span lang="EN-US">-</span><span style="font-family: 標楷體">具活性</span><span lang="EN-US">Smad2</span><span style="font-family: 標楷體">，已經被證實會和有活性的</span><span lang="EN-US">Ras</span><span style="font-family: 標楷體">共同作用，使不具侵略性的腫瘤轉變成會轉移的腫瘤；但</span><span lang="EN-US">Smad</span><span style="font-family: 標楷體">突變型不與</span><span lang="EN-US">TβRI</span><span style="font-family: 標楷體">結合，並會抑制乳癌細胞的轉移。最後，在</span><span lang="EN-US">Ras</span><span style="font-family: 標楷體">經惡性轉化的細胞中，顯性</span><span lang="EN-US">-</span><span style="font-family: 標楷體">不具活性且被截短的</span><span lang="EN-US">TβRI</span><span style="font-family: 標楷體">表現之後，則是會抑制腫瘤的產生能力</span><span lang="EN-US">(tumorigenicity)</span><span style="font-family: 標楷體">以及癌症移轉。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">癌症治療後的腫瘤再增殖</span><span lang="EN-US">(repopulation)</span><span style="font-family: 標楷體">與發展，是一眾所皆知的現象。它已被證實會在放射治療、化學治療以及手術摘除後發生。（在參考文獻</span><span lang="EN-US">37</span><span style="font-family: 標楷體">中有回顧）。</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">的濃度會對放射線有所反應而增加，也被發現與放射治療後之肺臟受傷有關，這是由膠原蛋白沉積、肺泡壁的增厚以及內皮細胞受傷所致。放射線引起的肺臟組織傷害，會因為施以抗</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">抗體而顯著地減少。在手術方面，已經有人提出，因為組織操作以及傷口復原而產生的生長激素過量釋放，包括</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">的過量釋放，會緊接著手術之後促進癌症移轉。確實如此，手術之後，循環中隨即發現了腫瘤細胞的存在，也發現腫瘤細胞數量的增加；而且在治療性切除直腸癌兩週之後，若循環中的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度居高不下，就表示癌症會很快地轉移至肝臟。相反地，在手術剛切除直腸腫瘤後，血清中的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度卻是顯著地降低的。最後，以化學</span><span lang="EN-US">-</span><span style="font-family: 標楷體">放射治療處理後期的頭頸部癌症，以及以化學治療處理非小型細胞肺癌</span><span lang="EN-US">(non-small-cell 
lung cancers)</span><span style="font-family: 標楷體">的情形下，循環中的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度已被證實和對治療的反應相關。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">
在本研究中，我們展示了放射治療與化學治療會提升循環中的</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度、循環中的癌症細胞數、以及癌症的移轉。這些效應會因為系統性地施加</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">而被阻斷，因此支持</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">為癌症轉移進展之肇因的說法。這些數據有數個臨床上的含意。第一，因癌症治療而增加的循環中</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度，應該要預前地探討與監控，因為它可能是一種標記，代表腫瘤注定要在治療之後快速地增長。第二，在循環中</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">濃度已被觀察到增加的病人，其身上帶有的腫瘤，可能會因我們施加</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">抑制劑而加強基本療程的效果，也可能可以抵銷與療程相關的毒性效應，例如放射線引起的組織傷害以及纖維化。我們預期，以我們現存的方法以及尚在臨床研發中的治療用</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">抑制劑，這些假說在不久的將來可以被證實。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">方法</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">藥劑與細胞株。</span></b><span lang="EN-US">2G7</span><span style="font-family: 標楷體">融合瘤是</span><span lang="EN-US">B. 
Fendly (Genentech)</span><span style="font-family: 標楷體">所贈。它是在</span><span lang="EN-US">Vanderbilt 
University Molecular Recognition Core facility</span><span style="font-family: 標楷體">被製出以及用親和純化法所得到的。重組的人類</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">以及為</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">用的</span><span lang="EN-US">Quantikine 
Elisa kit</span><span style="font-family: 標楷體">是從</span><span lang="EN-US"> R&amp;D 
Systems</span><span style="font-family: 標楷體">取得。表現</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">的細胞株是從</span><i><span lang="EN-US">MMTV/PyVmT</span></i><span style="font-family: 標楷體">基因轉殖鼠的乳腺腫瘤中取得。</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox
</sup></span><span style="font-family: 標楷體">及</span><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">細胞株是分別從</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox
</sup></span><span style="font-family: 標楷體">及</span><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">老鼠的乳腺癌中取得。我們在這些老鼠中使用</span><span lang="EN-US">Cre/Lox</span><span style="font-family: 標楷體">技術，有條件地從乳腺中刪除了</span><span lang="EN-US">TGF-βII</span><span style="font-family: 標楷體">。細胞被培養在一個</span><span lang="EN-US">37°C</span><span style="font-family: 標楷體">、濕化</span><span lang="EN-US">5%</span><span style="font-family: 標楷體">的溫箱中，並且培養於添加了</span><span lang="EN-US">10% 
FBS(HyClone)</span><span style="font-family: 標楷體">的</span><span lang="EN-US">DMEM(Cellgro; 
Mediatech Inc.)</span><span style="font-family: 標楷體">中。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>TGF-β1</b></span><b><span style="font-family: 標楷體">的生物檢測。</span></b><span style="font-family: 標楷體">貂肺臟內皮報告細胞</span><span lang="EN-US">(mink 
lung epithelial reporter cell)</span><span style="font-family: 標楷體">在</span><span lang="EN-US">PAI-1</span><span style="font-family: 標楷體">啟動子控制下，穩定地表現螢火蟲</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">。這些細胞接種於</span><span lang="EN-US">12-well
</span><span style="font-family: 標楷體">培養皿上</span> <span lang="EN-US">(2x10<sup>5</sup>/well)</span><span style="font-family: 標楷體">並且留置過夜供其貼附。已知濃度的可溶性</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">或肺臟組織的細胞裂解液</span><span lang="EN-US">(250μg/well)</span><span style="font-family: 標楷體">加入了三次，而這些細胞被留在</span><span lang="EN-US">5%</span><span style="font-family: 標楷體">二氧化碳、</span><span lang="EN-US">37°C</span><span style="font-family: 標楷體">的環境下培養了另外</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時。在清洗之後，這些細胞被收取至</span><span lang="EN-US">200μg/well</span><span style="font-family: 標楷體">的裂解緩衝液中</span><span lang="EN-US">(Dual 
Luciferase Kit; Promega)</span><span style="font-family: 標楷體">，</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">的活性則是在依據廠商提供的實驗步驟下進行了測量。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>DNA</b></span><b><span style="font-family: 標楷體">萃取與聚合&#37238;連鎖反應</span><span lang="EN-US">(PCR)</span></b><span style="font-family: 標楷體">。以石蠟固定的腫瘤切片被取出和重新添加水分。趁著還潮濕的時候，腫瘤部分以經消毒之刀片刮取至經消毒的</span><span lang="EN-US">eppendorf</span><span style="font-family: 標楷體">管中。</span><span lang="EN-US">DNA</span><span style="font-family: 標楷體">萃取是使用</span><span lang="EN-US">Instagene 
(Bio-Rad)</span><span style="font-family: 標楷體">並依廠商提供的實驗步驟所完成。</span><span lang="EN-US">DNA</span><span style="font-family: 標楷體">樣本儲存在</span><span lang="EN-US">-20°C</span><span style="font-family: 標楷體">，除非要另外使用。</span><span lang="EN-US">Cre</span><span style="font-family: 標楷體">誘導的</span><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup></span><span style="font-family: 標楷體">腫瘤重組，是用</span><span lang="EN-US">PCR</span><span style="font-family: 標楷體">引子以及前述之反應條件下所驗證的。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">眼窩後</span><span lang="EN-US">(retroorbital)</span><span style="font-family: 標楷體">血液收集以及</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">之定量</span></b><span style="font-family: 標楷體">。老鼠以</span><span lang="EN-US">1%-2% 
isofluorane</span><span style="font-family: 標楷體">麻醉。血液</span><span lang="EN-US">(</span><span style="font-family: 標楷體">約</span><span lang="EN-US">250μl/</span><span style="font-family: 標楷體">老鼠</span><span lang="EN-US">)</span><span style="font-family: 標楷體">採集於眼睛裡的結膜靜脈，作法是使用肝素化之</span><span lang="EN-US">Natelson 
tube (Fisher Scientific)</span><span style="font-family: 標楷體">然後再移轉到肝素化的</span><span lang="EN-US">(heparinized)</span><span style="font-family: 標楷體">玻璃管中。血漿的製備是使用</span><span lang="EN-US">Ficoll-Paque 
Plus (Amersham Biosciences)</span><span style="font-family: 標楷體">並依照廠商之使用說明進行，且增加了一個步驟，即在</span><span lang="EN-US">4°C</span><span style="font-family: 標楷體">下以</span><span lang="EN-US">10000g</span><span style="font-family: 標楷體">離心十分鐘以除去血小板。為測量</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">表現型細胞之培養基中的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">，</span><span lang="EN-US">1 
x 10<sup>6</sup> </span><span style="font-family: 標楷體">的細胞被塗佈在含在完全培養基的</span><span lang="EN-US">10 
mm</span><span style="font-family: 標楷體">盤上，並且供其貼附。該培養基在隔天被更換成無血清之培養基。隔夜培養後，細胞被施以</span><span lang="EN-US">1.25-7.5 
Gy</span><span style="font-family: 標楷體">。過</span><span lang="EN-US">72</span><span style="font-family: 標楷體">小時後，培養基經收集並以快速真空法濃縮</span><span lang="EN-US">(3 
ml to 500μl)</span><span style="font-family: 標楷體">。老鼠的血漿和受細胞條件培養基（</span><span lang="EN-US">cell-conditioned 
medium</span><span style="font-family: 標楷體">），均在下一步的</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">的</span><span lang="EN-US">Quantikine 
Elisa kit (R&amp;D Systems)</span><span style="font-family: 標楷體">中接受測試，依照的是廠商提供的實驗步驟。標準曲線以</span><span lang="EN-US">31.5–2,000 
pg/ml</span><span style="font-family: 標楷體">的人類重組</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">繪出後，被用來計算</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">在老鼠血漿與細胞培養基中的等量。每項標本都在另外的重製實驗中重複檢驗了三次。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>TGF-β2</b></span><b><span style="font-family: 標楷體">之定量。</span></b><span style="font-family: 標楷體">依照廠商提供之實驗步驟，在酸活化之後，血漿標本以</span><span lang="EN-US">TGF-β2 
Quantikine Elisa kit (R&amp;D Systems)</span><span style="font-family: 標楷體">測試。標準曲線以</span><span lang="EN-US">31.5–2,000 
pg/ml</span><span style="font-family: 標楷體">的人類重組</span><span lang="EN-US">TGF-β2</span><span style="font-family: 標楷體">繪出後，被用來計算</span><span lang="EN-US">TGF-β2</span><span style="font-family: 標楷體">在老鼠血漿的等量。每項標本都在另外的重製實驗中重複檢驗了三次。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">老鼠的放射處理。</span></b><i><span lang="EN-US">MMTV/PyVmT</span></i><span style="font-family: 標楷體">基因轉殖老鼠或正常的</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">母老鼠</span><span lang="EN-US">(Harlan)</span><span style="font-family: 標楷體">，在麻醉後把背部固定在鏡臺上。我們使用了單一的胸前輻射場，並使用了鉛塊掩護老鼠身體的其他部分。在某些實驗中則是使用了一個單一腹部輻射場。老鼠被施加</span><span lang="EN-US">300 
kVp </span><span style="font-family: 標楷體">的</span><span lang="EN-US">X</span><span style="font-family: 標楷體">光，其劑量為</span><span lang="EN-US"> 
2.05 Gy/min</span><span style="font-family: 標楷體">。所有的老鼠都依照此法規</span><span lang="EN-US">Institutional 
Animal Care and Use Committee of Vanderbilt University Medical Center</span><span style="font-family: 標楷體">，被留在一個專門的無病原空間中。在動物暴露在放射線或其他處理後，餵食正常食物，並且詳細觀察是否有任何情緒不穩的跡象。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">小紅莓</span><span lang="EN-US">(doxorubicin)</span><span style="font-family: 標楷體">的處理。</span></b><span lang="EN-US">53</span><span style="font-family: 標楷體">天大的</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">老鼠，經腹腔注射三次溶解於食鹽水液中的</span><span lang="EN-US">doxorubicin 
(Adriamycin; 5 mg/kg; Sigma-Aldrich</span><span style="font-family: 標楷體">），每次間隔</span><span lang="EN-US">21</span><span style="font-family: 標楷體">天，直到第</span><span lang="EN-US">95</span><span style="font-family: 標楷體">天止。經無效空白試劑或小紅莓處理之老鼠，其血液樣本和肺臟組織，都於第</span><span lang="EN-US">107</span><span style="font-family: 標楷體">天解剖取得。為了要檢查小紅莓處理之後的循環中腫瘤細胞，經無效空白試劑或小紅莓處理之老鼠，其血液在取得</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時後，又加入了單一劑量</span><span lang="EN-US">(5 
mg/kg)</span><span style="font-family: 標楷體">。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">偵測循環中腫瘤細胞。</span></b><span style="font-family: 標楷體">循環中腫瘤細胞之培養方法如前述，僅有少部分之修改。扼要地說，血液取得於心臟穿刺。細胞懸浮液（包括</span><span lang="EN-US">buffy 
coat</span><span style="font-family: 標楷體">以及紅血球）從血漿中分離出後，接種在</span><span lang="EN-US">6-well</span><span style="font-family: 標楷體">盤上，這些盤上佈有了生長激素減量之</span><span lang="EN-US">Matrigel 
(BD Biosciences)</span><span style="font-family: 標楷體">，並添加有</span><span lang="EN-US">DMEM</span><span style="font-family: 標楷體">、</span><span lang="EN-US">10%FBS</span><span style="font-family: 標楷體">，之後便於</span><span lang="EN-US">37°C</span><span style="font-family: 標楷體">、</span><span lang="EN-US">5%</span><span style="font-family: 標楷體">二氧化碳之溫箱中培養。隔天，在每個</span><span lang="EN-US">well</span><span style="font-family: 標楷體">使用了紅血球移除緩衝液</span><span lang="EN-US">(4.15 
g NH4Cl, 0.5 g NaHCO3, 0.0186 g disodium EDTA in 200 ml water)</span><span style="font-family: 標楷體">以及</span><span lang="EN-US">PBS</span><span style="font-family: 標楷體">，數次緩和的沖洗。</span><span lang="EN-US">DMEM</span><span style="font-family: 標楷體">與</span><span lang="EN-US">10%FBS(3ml/well)</span><span style="font-family: 標楷體">添加後，新鮮的培養基每三天將會補充一次。過了</span><span lang="EN-US">10-12</span><span style="font-family: 標楷體">天後，以人工計數大小為</span><span lang="EN-US">50μm</span><span style="font-family: 標楷體">以上之細胞集落。</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">表現是用免疫細胞化學方法來偵測的。扼要地說，吸出培養基、以</span><span lang="EN-US">PBS</span><span style="font-family: 標楷體">清洗</span><span lang="EN-US">wells</span><span style="font-family: 標楷體">，然後細胞集落以</span><span lang="EN-US">10%</span><span style="font-family: 標楷體">中性緩衝的福馬林</span><span lang="EN-US">(formalin)</span><span style="font-family: 標楷體">，在室溫下固定</span><span lang="EN-US">30</span><span style="font-family: 標楷體">分鐘，再用</span><span lang="EN-US">PBS</span><span style="font-family: 標楷體">清洗</span><span lang="EN-US">2</span><span style="font-family: 標楷體">次，再於室溫下與</span><span lang="EN-US">PBS</span><span style="font-family: 標楷體">中之</span><span lang="EN-US">3%BSA</span><span style="font-family: 標楷體">共存</span><span lang="EN-US">1</span><span style="font-family: 標楷體">小時。培養盤接著培養隔夜，於</span><span lang="EN-US">4°C</span><span style="font-family: 標楷體">置放於含有生物素標記的抗</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">的老鼠單株抗體</span><span lang="EN-US">(diluted 
1:500, BIOT-115L; Covance)</span><span style="font-family: 標楷體">。然後，加入與</span><span lang="EN-US">streptavidin</span><span style="font-family: 標楷體">結合之螢光二級抗體</span><span lang="EN-US">(Oregon 
Green 488; Invitrogen) </span><span style="font-family: 標楷體">室溫下</span><span lang="EN-US">1</span><span style="font-family: 標楷體">小時，之後使用</span><span lang="EN-US">Hoechst
</span><span style="font-family: 標楷體">細胞核染色法</span><span lang="EN-US">(1 μg/ml
</span><span style="font-family: 標楷體">十使用分鐘</span><span lang="EN-US">)</span><span style="font-family: 標楷體">。免疫螢光是以</span><span lang="EN-US">Leica 
DM IRB </span><span style="font-family: 標楷體">倒置顯微鏡所觀察的。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">
生產反轉錄病毒載體以及細胞轉導。</span></b><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">細胞，是以</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">之載體穩定轉染的。一個</span><span lang="EN-US">luciferase 
cassette</span><span style="font-family: 標楷體">從</span><span lang="EN-US">pGL3-Basic 
(Promega)</span><span style="font-family: 標楷體">裁切下來，並嵌入</span><span lang="EN-US">pMSCV-puro 
(Clontech)</span><span style="font-family: 標楷體">之多重複製位上。</span><span lang="EN-US">amphotropic 
packaging Phoenix cells </span><span style="font-family: 標楷體">
轉染後，產生感染性病毒顆粒，如前述。培養生長中</span><span lang="EN-US">(subconfluent)</span><span style="font-family: 標楷體">之癌症基因表現細胞，在</span><span lang="EN-US">4 
μg/ml Polybrene (Sigma-Aldrich)</span><span style="font-family: 標楷體">中，以病毒上清液轉導</span><span lang="EN-US">6</span><span style="font-family: 標楷體">小時，而含有病毒顆粒的培養基在</span><span lang="EN-US">6</span><span style="font-family: 標楷體">小時之後更換；在</span><span lang="EN-US">48</span><span style="font-family: 標楷體">小時後，再添加含有</span><span lang="EN-US">10%</span><span style="font-family: 標楷體">已經加熱變性之</span><span lang="EN-US">FCS</span><span style="font-family: 標楷體">的</span><span lang="EN-US">DMEM</span><span style="font-family: 標楷體">，並於</span><span lang="EN-US">7-10</span><span style="font-family: 標楷體">天後將抗藥的細胞集落合併。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">
腫瘤產生能力以及腫瘤轉移之研究。</span></b><span style="font-family: 標楷體">在</span><span lang="EN-US">1%–2% 
isofluorane </span><span style="font-family: 標楷體">之麻醉下，</span><i><span lang="EN-US">MMTV/PyVmT/Luc
</span></i><span style="font-family: 標楷體">細胞</span><span lang="EN-US">(2 × 10<sup>6
</sup>cells in 200 μl PBS) </span><span style="font-family: 標楷體">被注射於</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">母鼠的左側四號乳腺脂肪墊。扼要地說，在注入腫瘤細胞之前，脂肪墊便已經以手術使其暴露在外，而傷口以乾淨夾子密合，並於</span><span lang="EN-US">10</span><span style="font-family: 標楷體">天之後取走。每週以生物發光法檢查腫瘤兩次，並系列地以測徑器測量之。這些腫瘤的以立方公釐</span><span lang="EN-US">(mm<sup>3</sup>)</span><span style="font-family: 標楷體">計算之體積，是以此數學式計算：</span><i><span lang="EN-US">v
</span></i><span lang="EN-US">= (<i>w</i>2 × <i>l</i>)/2</span><span style="font-family: 標楷體">，</span><span lang="EN-US">v</span><span style="font-family: 標楷體">代表體積，</span><span lang="EN-US">w</span><span style="font-family: 標楷體">代表寬度，</span><span lang="EN-US">l</span><span style="font-family: 標楷體">代表長度。當腫瘤達到了</span><span lang="EN-US">200 
mm<sup>3</sup></span><span style="font-family: 標楷體">或更大的體積（約兩週時間），老鼠就被施以放射線處理，或是不作任何處理。老鼠繼續每週兩次接受生物發光法的監控觀察，直到實驗終結。兩週之後，將老鼠犧牲並取得基本的腫瘤與肺臟。以解剖顯微鏡計算肺臟表面之癌症轉移數，之後這些肺臟以</span><span lang="EN-US">10%</span><span style="font-family: 標楷體">中性緩衝之福馬林</span><span lang="EN-US">(formalin)</span><span style="font-family: 標楷體">固定之。固定好的腫瘤切片，以</span><span lang="EN-US">H&amp;E</span><span style="font-family: 標楷體">染色之，並以顯微鏡檢查是否有肺癌之轉移。血液是由心臟穿刺取得以如前述，測量</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">之濃度以及循環中之腫瘤細胞數。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family: 標楷體">在其他的情形裡，我們使用了</span><i><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">、</span><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flox</sup></span></i><span style="font-family: 標楷體">或</span><i><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup></span></i><span style="font-family: 標楷體">細胞來表現</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">。</span><span lang="EN-US">2.5 
× 10<sup>6</sup> </span><span style="font-family: 標楷體">之單一細胞懸浮液製備後，重新溶於無菌之</span><span lang="EN-US">PBS</span><span style="font-family: 標楷體">液中。</span><span lang="EN-US">0.5 
× 10<sup>6 </sup>(in 200 μl)</span><span style="font-family: 標楷體">的細胞被注射入</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">母鼠之側面尾部靜脈中。靜脈注射</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時後，腫瘤細胞於老鼠肺部之位置，以生物發光法確定之，並且自此之後每週追蹤兩次。為了要在活體內阻斷</span><span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">，在把</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">注入老鼠胸腔的前</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時，將</span><span lang="EN-US">15 
mg/kg</span><span style="font-family: 標楷體">的</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">注入老鼠腹腔內，每週兩次，持續進行，直到老鼠死亡。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">生物發光法顯影技術。</span></b><span style="font-family: 標楷體">要將生物發光之訊號與腫瘤負載量建立定量的對應關係，先以溶解於去離子水的</span>
<span lang="EN-US">luciferin substrate (d-luciferin potassium salt; Promega)</span><span style="font-family: 標楷體">進行腹腔注射</span><span lang="EN-US">(0.15 
mg/g body weight)</span><span style="font-family: 標楷體">，在注射之後</span><span lang="EN-US">12</span><span style="font-family: 標楷體">分鐘內取得影像。根據我們之前的時間記錄之實驗，在此時間記錄訊號高峰處之強度（資料未呈現）。在取得影像時，將老鼠以</span><span lang="EN-US">isofluorane</span><span style="font-family: 標楷體">麻醉。生物發光顯影是以</span><span lang="EN-US">Vanderbilt 
University Small Animal Imaging Center</span><span style="font-family: 標楷體">的</span><span lang="EN-US"> 
IVIS-200 </span><span style="font-family: 標楷體">顯影系統</span><span lang="EN-US"> (Xenogen)</span><span style="font-family: 標楷體">完成的。我們採用了</span><span lang="EN-US">3-5</span><span style="font-family: 標楷體">分鐘的整合計算時間，並使用</span><span lang="EN-US">on-chip 
binning of 8</span><span style="font-family: 標楷體">，以增加訊號</span><span lang="EN-US">-</span><span style="font-family: 標楷體">雜訊比。生物發光顯影之定量分析是以</span><span lang="EN-US">Living 
Image software (Xenogen)</span><span style="font-family: 標楷體">完成，我們在此定義了感興趣區域（</span><span lang="EN-US">regions 
of interest</span><span style="font-family: 標楷體">，</span><span lang="EN-US">ROI</span><span style="font-family: 標楷體">）並測量了</span><span lang="EN-US">integrated 
photon counts</span><span style="font-family: 標楷體">。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style="font-family: 標楷體">統計。</span></b><span style="font-family: 標楷體">所有的實驗數據均以雙尾</span><span lang="EN-US">Student’s
<i>t </i>test</span><span style="font-family: 標楷體">分析。</span><span lang="EN-US">P</span><span style="font-family: 標楷體">值小於</span><span lang="EN-US">0.05</span><span style="font-family: 標楷體">被視為顯著。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p><span lang="EN-US" style="font-size: 12.0pt; font-family: Times New Roman">
<br clear="all" style="page-break-before: always">
　</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1025" type="#_x0000_t75" style='width:359.25pt;
 height:153pt'>
 <v:imagedata src="cancer98.files/image001.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=479 height=204
src="cancer98.files/image002.gif" v:shapes="_x0000_s1025"><![endif]>&nbsp;</span></p>
<p class="MsoNormal" style="text-autospace: none"><b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-autospace: none"><b>
<span style="font-family: 標楷體">表一</span></b></p>
<p class="MsoNormal" style="text-autospace: none">
<span style="font-family: 標楷體">穩定表現</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">的</span><span lang="EN-US">MMTV/PyVmT</span><span style="font-family: 標楷體">細胞，被注射入</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">老鼠的右側鼠蹊乳腺脂肪墊中。擁有</span><span lang="EN-US">200mm<sup>3</sup></span><span style="font-family: 標楷體">以上腫瘤的老鼠，不加以放射處理，或是在胸腔施加</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">的放射處理。在</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時及</span><span lang="EN-US">2</span><span style="font-family: 標楷體">週後，以心臟穿刺取得血液，並測量細胞懸浮液在活體外形成細胞集落的能力，如「方法」文中所示。數據為兩個分別的實驗中，每組五隻老鼠的平均值</span><span lang="EN-US">±</span><span style="font-family: 標楷體">標準差。</span><span lang="EN-US">RT</span><span style="font-family: 標楷體">是指放射治療（</span><span lang="EN-US">radiation 
therapy</span><span style="font-family: 標楷體">）。在同一時間點下，</span><span lang="EN-US">A<i>P
</i>= 0.016 versus 0 Gy</span><span style="font-family: 標楷體">。</span><span lang="EN-US"><br clear="all" style="page-break-before: always">
<!--[if gte vml 1]><v:shape
 id="_x0000_s1026" type="#_x0000_t75" style='width:473.25pt;height:227.25pt'>
 <v:imagedata src="cancer98.files/image003.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=631 height=303
src="cancer98.files/image004.gif" v:shapes="_x0000_s1026"><![endif]></span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">圖一</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span style="font-family: 標楷體">放射線與化學治療增加循環中</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度。</span><span lang="EN-US"> 
(<b>A</b>) 10 Gy </span><span style="font-family: 標楷體">的放射線被施加於</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">老鼠之胸腔</span><span lang="EN-US">(thorax) 
(</span><span style="font-family: 標楷體">左</span><span lang="EN-US">)</span><span style="font-family: 標楷體">或骨盆腔</span><span lang="EN-US">(pelvis 
)(</span><span style="font-family: 標楷體">右</span><span lang="EN-US">)</span><span style="font-family: 標楷體">。</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時之後取得血液，血漿中之</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度以在「方法」中所述測量。</span><span lang="EN-US">(<b>B</b>)
</span><span style="font-family: 標楷體">八週大、帶有腫瘤之</span><i><span lang="EN-US">MMTV/PyVmT
</span></i><span style="font-family: 標楷體">老鼠，或非基因轉殖之</span><span lang="EN-US">FVB
</span><span style="font-family: 標楷體">老鼠，在四號乳腺脂肪墊帶有</span><span lang="EN-US">200mm<sup>3</sup></span><span style="font-family: 標楷體">以上大小之腫瘤，不作任何處理或施加</span><span lang="EN-US">10 
Gy </span><span style="font-family: 標楷體">於胸腔。血漿中</span><span lang="EN-US">TGF-β1
</span><span style="font-family: 標楷體">濃度，</span><span lang="EN-US">24</span><span style="font-family: 標楷體">小時後測量之。</span><span lang="EN-US">(<b>C</b>)
</span><span style="font-family: 標楷體">在第八週起，每隔</span><span lang="EN-US">21</span><span style="font-family: 標楷體">天，以空白試劑或腹腔注射小紅莓</span><span lang="EN-US"> 
(5 mg/kg i.p.)</span><span style="font-family: 標楷體">，處理基因轉殖老鼠三次。血漿中</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">濃度在第十五週測量之。</span><b><span lang="EN-US">A</span></b><span lang="EN-US">–<b>C
</b></span><span style="font-family: 標楷體">之數據代表三個不同的獨立實驗，每組使用三個實驗對象。</span><span lang="EN-US">(<b>D</b>) 
FVB</span><span style="font-family: 標楷體">老鼠胸腔被施加</span><span lang="EN-US">10 Gy</span><span style="font-family: 標楷體">。五週後，取得經放射線處理、控制組老鼠之肺臟，及其細胞裂解液</span><span lang="EN-US">(250 
μg/ml)</span><span style="font-family: 標楷體">，加到含有貂肺上皮細胞的</span><span lang="EN-US">triplicate 
wells</span><span style="font-family: 標楷體">，這些細胞會穩定地表現</span><span lang="EN-US">plasminogen 
activator inhibitor–1/luciferase reporter (PAI-1/luciferase reporter)</span><span style="font-family: 標楷體">。二十四小時後，測量</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">之表現，方法如「方法」部分中所述。圖示：</span><span lang="EN-US">*</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P
</span></i><span lang="EN-US">&lt; 0.05</span><span style="font-family: 標楷體">，</span><span lang="EN-US"> 
**</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P </span>
</i><span lang="EN-US">&lt; 0.01</span><span style="font-family: 標楷體">，</span><span lang="EN-US"> 
***</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P </span>
</i><span lang="EN-US">&lt; 0.001 </span><span style="font-family: 標楷體">相對於控制組。</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p><span lang="EN-US" style="font-size: 12.0pt; font-family: Times New Roman">
<br clear="all" style="page-break-before: always">
　</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US"><!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t75" style='width:473.25pt;height:314.25pt'>
 <v:imagedata src="cancer98.files/image005.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=631 height=419
src="cancer98.files/image006.gif" v:shapes="_x0000_s1027"><![endif]></span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">圖二</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span style="font-family: 標楷體">放射線與化學治療增加循環中腫瘤細胞量以及肺部之腫瘤轉移。</span><b><span lang="EN-US">(A)</span></b><span lang="EN-US"> 
MMTV/PyVmT</span><span style="font-family: 標楷體">母鼠在八週大時，接受胸腔放射線處理。在第十三週時，當實驗終結，以心臟穿刺取得血液，並量取其細胞懸浮液在體外產生細胞集落之能力，如「方法」中所述。</span><span lang="EN-US">CTCs</span><span style="font-family: 標楷體">代表循環中腫瘤細胞（</span><span lang="EN-US">circulating 
tumor cells</span><span style="font-family: 標楷體">）。在下面為一些具有代表性的影像，是由血液中取得、循環中單一個腫瘤細胞形成的細胞集落。基因轉殖成功的細胞集落，用</span><span lang="EN-US">PyVmT</span><span style="font-family: 標楷體">抗體和螢光之次級抗體處理，並以螢光顯微鏡觀察並估計之。</span><span lang="EN-US">(<b>B</b>)
</span><span style="font-family: 標楷體">與</span><b><span lang="EN-US">A</span></b><span lang="EN-US">
</span><span style="font-family: 標楷體">同樣之老鼠，在第十三週大時計算肺部表面癌症之轉移數目。</span><span lang="EN-US">A</span><span style="font-family: 標楷體">和</span><span lang="EN-US">B</span><span style="font-family: 標楷體">中之數據是代表三個獨立的實驗，每組中有四隻老鼠。從控制組以及經放射線處理之基因轉殖老鼠上，取得具代表性之</span><span lang="EN-US"> 
H&amp;E </span><span style="font-family: 標楷體">
染色的肺部組織切片。這些切片是胸腔放射處理後五週所取得，如下方所示。黑色箭頭所指為肺部癌症轉移。</span><span lang="EN-US">(<b>C</b>)
</span><span style="font-family: 標楷體">八週大、帶有腫瘤的</span> <i><span lang="EN-US">
MMTV/PyVmT </span></i><span style="font-family: 標楷體">基因轉殖老鼠，每隔</span><span lang="EN-US">21</span><span style="font-family: 標楷體">天以空白試劑或腹腔注射小紅莓</span><span lang="EN-US">(5 
mg/kg i.p.)</span><span style="font-family: 標楷體">處理共三次。此實驗於第十五週時終結，並計算肺部表面之癌症轉移數量。具代表性之</span><span lang="EN-US">H&amp;E</span><span style="font-family: 標楷體">染色肺部切片，其含有癌症轉移部分的中心如右方圖示。原始放大倍率為</span><span lang="EN-US">100</span><span style="font-family: 標楷體">倍。</span><span lang="EN-US">*</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P
</span></i><span lang="EN-US">&lt; 0.05</span><span style="font-family: 標楷體">，</span><span lang="EN-US"> 
**</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P </span>
</i><span lang="EN-US">&lt; 0.01 </span><span style="font-family: 標楷體">，相較於控制組。</span></p>
<p><span lang="EN-US" style="font-size: 12.0pt; font-family: Times New Roman">
<br clear="all" style="page-break-before: always">
　</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US"><!--[if gte vml 1]><v:shape
 id="_x0000_s1028" type="#_x0000_t75" style='width:473.25pt;height:204pt'>
 <v:imagedata src="cancer98.files/image007.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=631 height=272
src="cancer98.files/image008.gif" v:shapes="_x0000_s1028"><![endif]></span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">圖三</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span style="font-family: 標楷體">胸腔放射線會增加殖入腫瘤至肺部的癌症轉移。</span><span lang="EN-US">(<b>A</b>)
</span><span style="font-family: 標楷體">穩定表現</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">的</span><i><span lang="EN-US">MMTV/PyVmT
</span></i><span style="font-family: 標楷體">細胞，被注入同源</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">老鼠之乳腺脂肪墊中。之後，兩週一次，以生物發光顯影法監測腫瘤生長以及肺部癌症轉移。圖示為一具代表性之老鼠，圖為細胞注入兩週之後所攝</span><span lang="EN-US">(<b>B</b></span><span style="font-family: 標楷體">與</span><b><span lang="EN-US">C</span></b><span lang="EN-US">)</span><span style="font-family: 標楷體">。帶有至少</span><span lang="EN-US">200 
mm<sup>3</sup> PyVmT/Luc</span><span style="font-family: 標楷體">腫瘤的老鼠，以胸腔放射線</span><span lang="EN-US">(10 
Gy)</span><span style="font-family: 標楷體">處理之或不施加任何處理。</span><span lang="EN-US"> 
(<b>B</b>) </span><span style="font-family: 標楷體">
肺部癌症轉移在兩週之後定量。數據為每兩次實驗中之一次，每組五隻老鼠之平均值</span><span lang="EN-US"> ± </span>
<span style="font-family: 標楷體">標準差。</span><span lang="EN-US">**</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P
</span></i><span lang="EN-US">&lt; 0.01 </span><span style="font-family: 標楷體">
相較於控制組</span><span lang="EN-US"> (<b>C</b>) </span>
<span style="font-family: 標楷體">肺部與原發腫瘤之</span><span lang="EN-US">H&amp;E </span>
<span style="font-family: 標楷體">切片。原始放大倍率為</span><span lang="EN-US">100</span><span style="font-family: 標楷體">倍。</span></p>
<p><span lang="EN-US" style="font-size: 12.0pt; font-family: Times New Roman">
<br clear="all" style="page-break-before: always">
　</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US"><!--[if gte vml 1]><v:shape
 id="_x0000_s1029" type="#_x0000_t75" style='width:473.25pt;height:521.25pt'>
 <v:imagedata src="cancer98.files/image009.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=631 height=695
src="cancer98.files/image010.gif" v:shapes="_x0000_s1029"><![endif]></span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">圖四</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span style="font-family: 標楷體">放射線的先行處理，會使移轉的肺癌細胞更能夠拓展在原本無腫瘤的老鼠身上。</span><span lang="EN-US">(<b>A</b>)
<i>MMTV/PyVmT </i></span><span style="font-family: 標楷體">細胞，在加有不含血清之培養基之</span><span lang="EN-US">100-mm
</span><span style="font-family: 標楷體">培養皿裡，以</span><span lang="EN-US">1.25–7.5 
Gy</span><span style="font-family: 標楷體">處理。受細胞所影響之培養基在</span><span lang="EN-US">72</span><span style="font-family: 標楷體">小時後進行收集，並以如「方法」中所述之</span><span lang="EN-US">ELISA</span><span style="font-family: 標楷體">得知</span><span lang="EN-US">TGF-β1</span><span style="font-family: 標楷體">之濃度。</span><span lang="EN-US">(<b>B</b>)
</span><span style="font-family: 標楷體">穩定表現</span><span lang="EN-US">luciferase</span><span style="font-family: 標楷體">之</span><i><span lang="EN-US">MMTV/PyVmT
</span></i><span style="font-family: 標楷體">細胞，由尾部靜脈注入未交配之</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">母鼠。在接受細胞注射</span><span lang="EN-US">1</span><span style="font-family: 標楷體">小時之前，老鼠在圖中所標部分之胸部，以</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">處理之。在注射之後</span><span lang="EN-US">2</span><span style="font-family: 標楷體">週，肺部之癌症細胞以老鼠的生物發光法進行視覺觀察（頂圖）。某些情形中，肺臟在添加</span><span lang="EN-US">d-luciferin</span><span style="font-family: 標楷體">之後被手術移除，並於體外進行顯影（底圖）。控制組如左圖所示，受放射線處理之老鼠如右圖所示。</span><span lang="EN-US">(<b>C</b>)
</span><span style="font-family: 標楷體">具代表性的整體肺部載片（頂圖）以及控制組與放射線處理組之</span><span lang="EN-US">H&amp;E</span><span style="font-family: 標楷體">肺部切片</span><span lang="EN-US">(</span><span style="font-family: 標楷體">底圖；原放大倍率為</span><span lang="EN-US">100)</span><span style="font-family: 標楷體">。</span><span lang="EN-US">(<b>D</b>)
</span><span style="font-family: 標楷體">
在控制組與放射線處理老鼠中，肺部表面癌症轉移之定量（左圖）與肺部重量（右圖）。數據為兩個獨立實驗中，每組的五隻老鼠的平均值</span><span lang="EN-US">±</span><span style="font-family: 標楷體">標準差。圖示：</span><span lang="EN-US">**</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P
</span></i><span lang="EN-US">&lt; 0.01</span><span style="font-family: 標楷體">，</span><span lang="EN-US"> 
***</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P </span>
</i><span lang="EN-US">&lt; 0.001 </span><span style="font-family: 標楷體">，相較於控制組。</span></p>
<p><span lang="EN-US" style="font-size: 12.0pt; font-family: Times New Roman">
<br clear="all" style="page-break-before: always">
　</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US"><!--[if gte vml 1]><v:shape
 id="_x0000_s1030" type="#_x0000_t75" style='width:473.25pt;height:312pt'>
 <v:imagedata src="cancer98.files/image011.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=631 height=416
src="cancer98.files/image012.gif" v:shapes="_x0000_s1030"><![endif]></span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">圖五</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">TGF-β</span><span style="font-family: 標楷體">中和抗體</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">，阻斷了放射線誘導增加的肺部癌症轉移。</span><span lang="EN-US">(<b>A</b></span><span style="font-family: 標楷體">和</span><b><span lang="EN-US">B</span></b><span lang="EN-US">)
</span><span style="font-family: 標楷體">八週大、</span> <span style="font-family: 標楷體">
帶有腫瘤的</span><i><span lang="EN-US">MMTV/PyVmT</span></i><span style="font-family: 標楷體">老鼠於胸腔接受</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">處理。在圖中標出之部分，老鼠被每週兩次施以</span><span lang="EN-US">15 
mg/kg </span><span style="font-family: 標楷體">的</span><span lang="EN-US">2G7</span><span style="font-family: 標楷體">，直到第十三週。此時進行肺部表面之癌症轉移計數。</span><span lang="EN-US">(<b>A</b>)
</span><span style="font-family: 標楷體">數據為每組中五隻老鼠的平均值</span> <span lang="EN-US">±
</span><span style="font-family: 標楷體">標準差。</span><span lang="EN-US">(<b>B</b>)
</span><span style="font-family: 標楷體">代表性的</span><span lang="EN-US">H&amp;E </span>
<span style="font-family: 標楷體">染色肺部切片。此實驗重複一次取得了類似的結果。</span><span lang="EN-US">(<b>C</b>)
</span><span style="font-family: 標楷體">
當實驗終結，以心臟穿刺取得血液，並量取其細胞懸浮液在體外產生細胞集落之能力，如「方法」部分中所述。</span><span lang="EN-US">(<b>D</b>)
</span><span style="font-family: 標楷體">在第十三週，經過胸腔放射處理、帶有腫瘤的基因轉殖鼠，收集血液。細胞懸浮液如</span><span lang="EN-US">C</span><span style="font-family: 標楷體">圖中情形，在</span><span lang="EN-US">20 
μg/ml 2G7</span><span style="font-family: 標楷體">或</span><span lang="EN-US">PBS</span><span style="font-family: 標楷體">環境下，塗佈於培養盤上。</span><span lang="EN-US">10-12</span><span style="font-family: 標楷體">天後，人工計數等於或大於</span><span lang="EN-US">50 
μm</span><span style="font-family: 標楷體">的細胞集落。數據為每組五隻老鼠的平均值</span><span lang="EN-US">±</span><span style="font-family: 標楷體">標準差。</span><span lang="EN-US">*</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P
</span></i><span lang="EN-US">&lt; 0.05</span><span style="font-family: 標楷體">，</span><span lang="EN-US"> 
**</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P </span>
</i><span lang="EN-US">&lt; 0.01 </span><span style="font-family: 標楷體">相較於控制組。</span></p>
<p><span lang="EN-US" style="font-size: 12.0pt; font-family: Times New Roman">
<br clear="all" style="page-break-before: always">
　</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US"><!--[if gte vml 1]><v:shape
 id="_x0000_s1031" type="#_x0000_t75" style='width:473.25pt;height:309pt'>
 <v:imagedata src="cancer98.files/image013.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=631 height=412
src="cancer98.files/image014.gif" v:shapes="_x0000_s1031"><![endif]></span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span lang="EN-US">&nbsp;</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<b><span style="font-family: 標楷體">圖六</span></b></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span style="font-family: 標楷體">腫瘤細胞中不存在</span><span lang="EN-US">TGFβRII</span><span style="font-family: 標楷體">，能抵銷受放射線誘發的肺部癌症轉移之增加。</span><span lang="EN-US">(<b>A</b>–<b>C</b>)
</span><span style="font-family: 標楷體">未交配的、八週大的</span><span lang="EN-US">FVB</span><span style="font-family: 標楷體">母鼠，從尾部靜脈注入穩定表現</span><span lang="EN-US"> 
luciferase</span><span style="font-family: 標楷體">的</span><i><span lang="EN-US">PyVmT/TGFBR2<sup>flox/flo</sup></span></i><sup><span lang="EN-US">x</span></sup><span lang="EN-US">
</span><span style="font-family: 標楷體">與</span> <i><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup></span></i><span lang="EN-US">
</span><span style="font-family: 標楷體">細胞。這些老鼠在注射腫瘤細胞之前，一組接受、一組未接受胸腔的</span><span lang="EN-US">10 
Gy</span><span style="font-family: 標楷體">處理。兩週後，以生物發光</span><span lang="EN-US">(A)</span><span style="font-family: 標楷體">、組織染色</span><span lang="EN-US">(B)</span><span style="font-family: 標楷體">、以及人工計數肺部表面癌症轉移</span><span lang="EN-US">(C)</span><span style="font-family: 標楷體">的方法，來測定肺部表面癌症轉移，如「方法」中所述。資料為每組中四隻老鼠的平均值</span><span lang="EN-US">±
</span><span style="font-family: 標楷體">標準差。</span><span lang="EN-US"> (<b>D</b>)
</span><span style="font-family: 標楷體">兩組細胞株的基因體</span><span lang="EN-US">DNA</span><span style="font-family: 標楷體">之</span><span lang="EN-US">PCR</span><span style="font-family: 標楷體">結果，顯示重組片段的僅存在於</span><i><span lang="EN-US">PyVmT/TGFBR2<sup>KO</sup>
</span></i><span style="font-family: 標楷體">細胞中。</span><span lang="EN-US">**</span><span style="font-family: 標楷體">表示</span><i><span lang="EN-US">P
</span></i><span lang="EN-US">&lt; 0.01 </span><span style="font-family: 標楷體">
相較於控制組。</span></p>
<p><span lang="EN-US" style="font-size: 12.0pt; font-family: Times New Roman">
<br clear="all" style="page-break-before: always">
　</span></p>
<p class="MsoNormal" style="text-autospace: none">
<span style="font-family: 標楷體">譯者：</span><span lang="EN-US">Jeffrey Chu at 
Hsinchu, Taiwan. 2009/4/4</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span lang="EN-US">&nbsp;</span></p>
<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; text-autospace: none">
<span style="font-family: 標楷體">不免有所遺漏、錯誤，敬請參考與指正，謝謝。</span></p>

</body>

</html>
